Associated Papers
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
Characteristics predicting reduced penetrance variants in the high-risk cancer predisposition gene TP53.
Fortuno C et al.
Hgg Advances, 2025
TP53 p.R181H is enriched in the Swedish cohort (SWEP53) and associated with a distinct breast and prostate phenotype.
Sun Zhang A et al.
Scientific Reports, 2025
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.
Funk JS et al.
Nature Genetics, 2025
TP53 germline pathogenic variants in modern humans were likely originated during recent human history.
Kou SH et al.
Nar Cancer, 2023
p53 partial loss-of-function mutations sensitize to chemotherapy.
Klimovich B et al.
Oncogene, 2022
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
Comprehensive Identification of Deleterious TP53 Missense VUS Variants Based on Their Impact on TP53 Structural Stability.
Tam B et al.
International Journal of Molecular Sciences, 2021
Pathogenic genetic variants from highly connected cancer susceptibility genes confer the loss of structural stability.
Reza MN et al.
Scientific Reports, 2021
Pathogenic nsSNPs that increase the risks of cancers among the Orang Asli and Malays.
Khoruddin NA et al.
Scientific Reports, 2021
Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy.
Timofeev O et al.
Cancers, 2021
Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.
Timofeev O et al.
The Embo Journal, 2019
p53 defies convention again: a p53 mutant that has lost tumor suppression but still can kill.
Manfredi JJ
The Embo Journal, 2019
From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion.
Quinn EA et al.
Cold Spring Harbor Molecular Case Studies, 2019
How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2018
StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors.
Sen M et al.
Cancer Medicine, 2017
Clinical Overview of MDM2/X-Targeted Therapies.
Burgess A et al.
Frontiers in Oncology, 2016
Structure-Based Analysis Reveals Cancer Missense Mutations Target Protein Interaction Interfaces.
Engin HB et al.
Plos One, 2016
Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers.
Ashworth J et al.
Nucleic Acids Research, 2014
TP53 mutants in the tower of babel of cancer progression.
Bisio A et al.
Human Mutation, 2014
Oxidized DJ-1 inhibits p53 by sequestering p53 from promoters in a DNA-binding affinity-dependent manner.
Kato I et al.
Molecular and Cellular Biology, 2013
p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system.
Andreotti V et al.
Plos One, 2011
Life or death: p53-induced apoptosis requires DNA binding cooperativity.
Schlereth K et al.
Cell Cycle (georgetown, Tex.), 2010
DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis.
Schlereth K et al.
Molecular Cell, 2010
Monocytic leukemia zinc finger (MOZ) interacts with p53 to induce p21 expression and cell-cycle arrest.
Rokudai S et al.
The Journal of Biological Chemistry, 2009
Dimerization of the core domain of the p53 family: a computational study.
Madhumalar A et al.
Cell Cycle (georgetown, Tex.), 2009
The oncogenic roles of p53 mutants in mouse models.
Lozano G
Current Opinion in Genetics & Development, 2007
Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations.
Soussi T et al.
Human Mutation, 2005
A novel p53 mutant retained functional activity in lung carcinomas.
Ko JL et al.
Dna Repair, 2002
RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome.
Stein T et al.
Oncogene, 2002
Identification of a tumor-derived p53 mutant with novel transactivating selectivity.
Pan Y et al.
Oncogene, 2000
The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression.
Venot C et al.
The Embo Journal, 1998
A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear:cytoplasmic shuttling defect.
Crook T et al.
Oncogene, 1998
Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene.
Gorgoulis VG et al.
British Journal of Cancer, 1998